La tétracycline, connue sous le nom commercial Sumycin, agit en bloquant la fixation de l’ARNt sur la sous-unité 30S ribosomale, interrompant l’élongation de la chaîne protéique bactérienne. Ce mécanisme confère une activité sur un spectre large, incluant bactéries Gram positives, Gram négatives, rickettsies et spirochètes. Sa biodisponibilité digestive varie selon la prise alimentaire et les interactions avec les ions divalents comme calcium et magnésium. Sa diffusion tissulaire est importante, notamment dans les voies respiratoires et génito-urinaires. L’élimination se fait par voie rénale et biliaire. Les effets indésirables incluent photosensibilisation, troubles digestifs et coloration dentaire en cas d’administration précoce. Les guides thérapeutiques mentionnent sumycin prix, en soulignant la nécessité de restreindre son utilisation afin de limiter les résistances acquises.

Bdi_aktuell_2009_literaturliste_1_1:bdi_aktuell_2007_literaturliste_01.qxd.qxd

Paroxysmale nächtliche Hämoglobinurie (PNH)
Pathogenese, Diagnostik und Therapie
A. Röth, U. Dührsen, H. Schrezenmeier, J. Schubert Literatur
1 Dacie JV, Lewis SM. Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of
the disease. Ser Haematol 1972; 5: 3–23 2 Fachinformation Soliris® 2007
Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101: 1236–42 3 Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal
hemoglobinuria (PNH). Blood 2003; 102: 3587–91 4 Hegenbart U, Niederwieser D, Forman S et al. Hematopoietic cell transplantation from related and unrelated
donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 2003; 9: 689–97 5 Hill A, Rother RP, Hillmen P. Improvement in the symptoms of smooth muscle dystonia during eculizumab
therapy in paroxysmal nocturnal hemoglobinuria. Haematologica 2005; 90: ECR40– 6 Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients
with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552–9 7 Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria.
8 Hillmen P, Muus P, Dührsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in
patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123–4128 9 Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal
hemoglobinuria. N Engl J Med 2006; 355: 1233–43 10 Hugel B, Socié G, Vu T et al. Elevated levels of circulating procoagulant microparticles in patients with
paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451–6 11 Issaragrisil S, Piankijagum A, Tang-naitrisorana Y. Corticosteroids therapy in paroxysmal nocturnal
hemoglobinuria. Am J Hematol 1987; 25: 77–83 12 Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol
13 Parker C, Omine M, Richards S et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
14 Richards SJ, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with
paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom 2007; 72: 291–8 15 Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76: 63–93
16 Rosse WF, Hillmen P, Schreiber AD. Immune-mediated hemolytic anemia. Hematology (Am Soc Hematol Educ
17 Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular
plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293: 1653–62 18 Saso R, Marsh J, Cevreska L et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria.
19 Schubert J, Alvarado M, Uciechowski P et al. Diagnosis of paroxysmal nocturnal haemoglobinuria using
immunophenotyping of peripheral blood cells. Br J Haematol 1991; 79: 487–92 20 Strübing P. Paroxysmale Haemoglobinurie. Dtsch Med Wochenschr 1882; 8: 1–3
21 Strübing P. Paroxysmale Haemoglobinurie. Dtsch Med Wochenschr 1882; 8: 17–19

Source: http://www.deutscher-internistentag.de/fileadmin/PDF/bdi_aktuell/2009/04/BDI_aktuell_4_2009_Literaturliste_1.pdf.pdf